Latest research Russia – Feb. 2, CNN reports an interim analysis of the results of the third phase of the vaccine trial. Sputnik V COVID-19 vaccine Which was developed by Russia as being effective against COVID-19 kinds of symptoms Up to 91.6% and anti-performance COVID-19 kinds of medium and severe 100% fully
This is the latest in progress in the study of the Sputnik V vaccine after Russia has been criticized by the scientific community. Since the vaccine was approved for public use in August last year. Before the third trial Or the final phase will finish
The preliminary findings are published in the magazine. Lancet Based on data gathered from 19,866 participants in the trial, 3 out of 4, or 14,964, received two doses of the vaccine, 1 in 4 the remaining or 4,902 received a placebo.
It appears that after the group received the first dose of the vaccine for 21 days, COVID-19 cases were confirmed. 16 subjects and the placebo group Confirmation of COVID-19 cases The symptomatic type of up to 62 people was 91.6% effective.
The number of trials involved 2,144 people aged 60 and over, and a sub-analysis of this group found that The vaccine is well tolerated and has a near 91.8% efficacy.
The research team also analyzed the effectiveness of the vaccine against COVID-19. Moderate and severe and 21 days after vaccination showed that in the actual vaccinated group, there were no reports of COVID-19 cases. Moderate or severe type In the placebo group, COVID-19 cases were reported. Moderate or severe type 20 people
While serious vaccine adverse events were as low as 0.2% in the real vaccine group. And most of the side effects are mild, such as pain at the vaccination site. Flu-like symptoms And low energy levels in the body
However, the analysis included only COVID-19 patients showing symptoms, and the study authors indicated more research is needed to understand. 1. The efficacy of the Sputnik V vaccine against COVID-19 was asymptomatic, 2. Transmission, and 3. Duration of prevention.
Additionally, most of the participants in the trial were white. Further research is needed to verify results in other ethnic groups. The experiments are still ongoing and the goal is to gather all the participants. 40,000 people
Dr.Inna Vedol Jikova At Russia’s National Kamaleya Research Center for Epidemiology and Microbiology, the developer of the Sputnik V vaccine and co-author of the study said the analysis indicated that Sputnik Vmi vaccine Performance and Immunity High and Durability Good in trial participants aged 18 and over.
Participants were tested for PCR Covid-19 (PCR Covid-19) when receiving a second vaccine. And have been further tested for symptoms of a respiratory infection or not
Sputnik V vaccine is a two-dose adenoviral vector vaccine that uses two adenoviruses in each dose and spaced 21 days.
With this vaccine Adinoviruses are converted so they can transmit genetic material from the coronavirus. It enters the body and receives cells to express the disruptive stimulation found in the virus and stimulate the immune response. It is similar to the vaccine developed by Astraseneca and Johnson & Johnson
The study authors said Using a different adenovirus vector for booster vaccination may help create a more powerful immune response.
Another advantage of adenovirus vaccines is that they do not need to be stored and transported in very cold temperatures. The Sputnik V vaccine just needs to be refrigerated normally. And costs a fee of 10 US dollars or about 300 baht by Russia’s Direct Investment Fund (Russian Direct Investment Fund: RDIF) is the fund, producer and responsible person for vaccine sales worldwide.
The Sputnik V vaccine is approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia and Armenia More than 2 million people have been injected around the world.
Lao He received the COVID vaccine. Russia delivered 2 million doses.
Russia gets COVID vaccine free, 70 Moscow clinics Put the risk group first